Atrial Fibrillation, Myocardial Infarction
Conditions
Keywords
Acute Coronary Syndromes, Atrial Fibrillation, Anticoagulant therapy, Implantable device, Telecardiology.
Brief summary
Patients with Acute Coronary Syndrome associated with de novo atrial fibrillation are randomized to benefit from either a conventional therapy associating dual antiplatelet therapy (DAPT) and anticoagulant or DAPT and an implantable monitoring device with a follow-up by telecardiology
Detailed description
Acute Coronary Syndrome associated with de novo atrial fibrillation is not uncommon. It worsens the short-term, medium-term and long-term prognosis. It is then usual, according to ESC recommendations, to add to the DAPT, an anticoagulant treatment, which is a source of iatrogenic events, in particular hemorrhagic events. However, recurrence is not a certainty. Albeit variable, its highest rate is estimated to be 38%. Consequently, a well-conducted screening of atrial fibrillation recurrence could allow to treat only selected recurrent patients. At present, this screening can be carried out in a reliable and minimally invasive way with an implantable device with telecardiology. We propose a study for these patients with ACS associated with de novo AF. The study will be multicenter, randomized, open-label, with two arms: patient conventionally treated (DAPT + AC) and patient treated by DAPT + implantable device and followed for two years by telecardiology. This patient will only reintegrate the first arm in case of AF recurrence.
Interventions
DRUGnon-systematic prescription of anticoagulant therapy
the prescription of anticoagulant is managed by an implantable device follow up
Sponsors
Centre Hospitalier de PAU
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
prospective trial of therapeutic strategy, interventional, randomized and open-label, national and multicenter
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Atrial fibrillation diagnosed before hospitalization for acute coronary syndrome, whether treated or not. * Atrial fibrillation still present at inclusion time. * Transient atrial fibrillation due to a reversible disorder (thyrotoxycosis, pulmonary embolism, recent surgery). * Acute coronary syndrome that has not been revascularized. * Acute coronary syndrome surgically treated (bypass). * Patient already on anticoagulant therapy. * Scheduled aortocoronary bypass. * Creatinine clearance \< 30 ml per minute.
Exclusion criteria
Pathologic criteria : * Atrial fibrillation diagnosed before hospitalization for acute coronary syndrome, whether treated or not. * Atrial fibrillation still present at inclusion time. * Transient atrial fibrillation due to a reversible disorder (thyrotoxycosis, pulmonary embolism, recent surgery). * Acute coronary syndrome that has not been revascularized. * Acute coronary syndrome surgically treated (bypass). * Patient already on anticoagulant therapy. * Scheduled aortocoronary bypass. * Creatinine clearance \< 30 ml per minute. Bleeding risks : * Contraindications to anticoagulant therapy. * Active internal hemorrhage, clinically significant bleeding, bleeding non accessible to compression or bleeding diathesis within 30 days prior to selection visit. * Platelet count \< 90000/µL at the selection visit. * Bleeding event in the twelve months prior to inclusion. * Bleeding events detected either clinically or biologically (hemoglobinemia \< 10g/dl). * Elective surgery. Comorbidities : * Cardiogenic shock. * Hyperthyroidism. * Prior history of significant liver disease (acute hepatitis, active chronic hepatitis, cirrhosis) or liver function disorder detected at selection visit. * Significant mitral valvular heart disease. General : * Patient under 18. * Non menopausal woman or without contraception. * Patient whose physical and / or mental health may have an impact on the compliance to the study. * Participation in another biomedical research study (interventional or noninterventional) or participation in a research study within the 30 days prior to inclusion. * Protected adults (under judicial protection, guardianship, or supervision).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of hemorrhagic events | 2 years | To show that the introduction of an anticoagulant treatment in patients with ACS and de novo AF based on the data furnished by an implantable holter with remote monitoring is safer in terms of occurrence of hemorrhagic events than the systematic introduction of an anticoagulant treatment associated to DAPT based on the CHA2DS2-VASc score. CHA2DS2-Vasc score, derived from CHADS2 score. It assesses the risk of a person with atrial fibrillation (AF) without associated valve pathology, to experience an ischemic stroke, in other words, to assess the need for anticoagulant treatment. It ranges from 0 to 10. A score of 0 is considered a low risk. A score greater than or equal to 2 is considered a significant risk of embolic complication and should lead to discussion of the introduction of oral anticoagulant therapy. |
Countries
France
Outcome results
None listed